Sign In
Buy DCPH
$25.59
+0 (+0%)
At Close: Sep 09, 2024
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (UHS), Deciphera Pharmaceuticals (DCPH)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (
UHS
–
Research Report
), Deciphera Pharmaceuticals (
DCPH
–
Research Report
) an
U.S. RESEARCH ROUNDUP- Hormel Foods, Tyson Foods, Zebra Technologies
05:49pm, Wednesday, 29'th Apr 2020
Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Hormel Foods, Tyson Foods and Zebra Technologies, on
Wednesday.
HIGHLIGHTS
Leerink Partners Keeps Their Hold Rating on Deciphera Pharmaceuticals (DCPH)
10:57am, Wednesday, 29'th Apr 2020
In a report released today,
Andrew Berens
from Leerink Partners maintained a
Hold
rating on Deciphera Pharmaceuticals (
DCPH
–
Research Report
), with a price target of
$55.00
. The company’s shar
6 Stocks To Watch: AMC, BLDR, CREX, KURA, NGL, RRGB
12:00am, Wednesday, 29'th Apr 2020
Stocks Analysis by Harry Boxer covering: MGM Resorts International, Fluor Corporation, Builders FirstSource Inc, Avadel Pharmaceuticals PLC. Read Harry Boxer's latest article on Investing.com
Blueprint Medicines Tumbles 20.8% on Phase 3 Study Failure
03:19pm, Tuesday, 28'th Apr 2020
A closely watched drug candidate didn't meet the primary endpoint of a late-stage trial, which creates a wide-open opportunity for a competitor.
Blueprint Sinks On Adverse Clinical Readout, Deciphera Moves Higher
03:18pm, Tuesday, 28'th Apr 2020
Blueprint Medicines Corp (NASDAQ: BPMC) shares were taking a beating Tuesday after the company announced a negative late-stage readout for its lead asset avapritinib in...
JonesTrading Sticks to Its Buy Rating for Deciphera Pharmaceuticals (DCPH)
01:42pm, Tuesday, 28'th Apr 2020
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH). The company's shares closed last
JonesTrading Sticks to Its Buy Rating for Deciphera Pharmaceuticals (DCPH)
01:42pm, Tuesday, 28'th Apr 2020
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report).
BBBY, DVAX among premarket gainers
01:22pm, Tuesday, 28'th Apr 2020
Broadwind Energy (NASDAQ:BWEN) +60%. on $19M order.TrovaGene (NASDAQ:TROV) +44% on new positive results from its ongoing Phase 1b/2 clinical trial of onvansertib in combination with FOLFIRI and Avast
Blueprint's avapritinib pain is Deciphera's gain, up 16%
11:57am, Tuesday, 28'th Apr 2020
Deciphera Pharmaceuticals (NASDAQ:DCPH) is up 16% premarket on light volume on the heels on Blueprint Medicines' plunge after announcing unsuccessful results from late-stage study of avapritinib in�
Blueprint Medicines lead drug flunks GIST study; shares down 15% premarket
11:51am, Tuesday, 28'th Apr 2020
Blueprint Medicines (NASDAQ:BPMC) slumps 15% premarket in reaction to its announcement that a Phase 3 clinical trial, VOYAGER, evaluating lead candidate avapritinib, branded as Ayvakit, in patients
Deciphera Pharmaceuticals, Inc. to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5, 2020
11:00am, Tuesday, 28'th Apr 2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its first q
Covid-19 : comment la dématérialisation dope la résilience de Butagaz
06:00am, Tuesday, 28'th Apr 2020
Des envois postaux
réduits à la portion congrue
, personne dans les bureaux pour ouvrir le courrier et récupérer les factures ou les...
The Best Coffee Makers of 2020 | Digital Trends
09:04pm, Monday, 27'th Apr 2020
Looking for the perfect coffee maker for your favorite brews? From simple to complex, you'll find the most efficient and smartest models available on our list.
